On Tuesday, biotech and pharmaceutical companies urged president Donald Trump to reconsider his decision to end former president Barack Obama’s policy protecting undocumented immigrants who arrived in the U.S. as children.
Attorney general Jeff Sessions said Tuesday morning that Trump would move to halt the Deferred Action for Childhood Arrivals program in six months, unless Congress moves to protect it. The president & CEO of Decibel Therapeutics, Steven Holtzman, and the president & CEO of Ovid Therapeutics, Jeremy Levin, called on the president to “reverse your decision” in a letter that has since received add-on signatures from folks like the CEO of Biogen (NSDQ:BIIB), Michel Vounatsos.
Get the full story at our sister site, Drug Delivery Business News.
The post Biotech, pharma chime in over Trump’s move to halt immigration program appeared first on MassDevice.
from MassDevice http://ift.tt/2eKz48U
Cap comentari:
Publica un comentari a l'entrada